Eight patients experienced leukemia relapse: six (75.0%) with CD19+CD22+ relapse, one (12.5%) with CD19−CD22+ relapse, and one (12.5%) with CD19−CD22− relapse (Fig. S5A and Table S8). This evidence concerns the gene CD19 and leukemia.